Osteoimmunology: the conceptual framework unifying the immune and skeletal systems
K Okamoto, T Nakashima, M Shinohara… - Physiological …, 2017 - journals.physiology.org
The immune and skeletal systems share a variety of molecules, including cytokines,
chemokines, hormones, receptors, and transcription factors. Bone cells interact with immune …
chemokines, hormones, receptors, and transcription factors. Bone cells interact with immune …
Molecular and cellular functions of CTLA-4
S Van Coillie, B Wiernicki, J Xu - Regulation of Cancer Immune …, 2020 - Springer
Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is an inhibitory receptor belonging to
the CD28 immunoglobulin subfamily, expressed primarily by T-cells. Its ligands, CD80 and …
the CD28 immunoglobulin subfamily, expressed primarily by T-cells. Its ligands, CD80 and …
Citrullination in the pathology of inflammatory and autoimmune disorders: recent advances and future perspectives
O Ciesielski, M Biesiekierska, B Panthu… - Cellular and Molecular …, 2022 - Springer
Numerous post-translational modifications (PTMs) govern the collective metabolism of a cell
through altering the structure and functions of proteins. The action of the most prevalent …
through altering the structure and functions of proteins. The action of the most prevalent …
Control of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathways
BT Fife, JA Bluestone - Immunological reviews, 2008 - Wiley Online Library
Classically, the CD28/cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4) and B7 families of cell
surface molecules regulate complex signaling pathways that profoundly affect T‐cell …
surface molecules regulate complex signaling pathways that profoundly affect T‐cell …
New therapies for treatment of rheumatoid arthritis
JS Smolen, D Aletaha, M Koeller, MH Weisman… - The lancet, 2007 - thelancet.com
Rheumatoid arthritis is characterised by pain, swelling, and destruction of joints, with
resultant disability. Only disease-modifying antirheumatic drugs can interfere with the …
resultant disability. Only disease-modifying antirheumatic drugs can interfere with the …
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition
MC Genovese, JC Becker, M Schiff… - … England Journal of …, 2005 - Mass Medical Soc
Background A substantial number of patients with rheumatoid arthritis have an inadequate
or unsustained response to tumor necrosis factor α (TNF-α) inhibitors. We conducted a …
or unsustained response to tumor necrosis factor α (TNF-α) inhibitors. We conducted a …
Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 …
P Emery, GR Burmester, VP Bykerk… - Annals of the …, 2015 - ard.bmj.com
Objectives To evaluate clinical remission with subcutaneous abatacept plus methotrexate
(MTX) and abatacept monotherapy at 12 months in patients with early rheumatoid arthritis …
(MTX) and abatacept monotherapy at 12 months in patients with early rheumatoid arthritis …
Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig
JM Kremer, R Westhovens, M Leon… - … England Journal of …, 2003 - Mass Medical Soc
Background Effective new therapies are needed for rheumatoid arthritis. Current therapies
target the products of activated macrophages; however, T cells also have an important role …
target the products of activated macrophages; however, T cells also have an important role …
Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy
AL Taylor, CJE Watson, JA Bradley - Critical reviews in oncology …, 2005 - Elsevier
Effective immunosuppression is an essential pre-requisite for successful organ
transplantation and improvements in outcome after transplantation have to a large extent …
transplantation and improvements in outcome after transplantation have to a large extent …
Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial
JM Kremer, HK Genant, LW Moreland… - Annals of internal …, 2006 - acpjournals.org
Background: The selective co-stimulation modulator abatacept demonstrated efficacy for
treating rheumatoid arthritis in early clinical studies. Objective: To evaluate the effects of …
treating rheumatoid arthritis in early clinical studies. Objective: To evaluate the effects of …